Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,472
datasets available to search
ShareScore release 0.9.0
Dataset results
1,472 results for “EGFR”
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
ClinicalTrials.gov study NCT02006043. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
ClinicalTrials.gov study NCT06050980. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT06992739. IPD Sharing: NO. Countries: 0. Publications: 0.
Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT00903461. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
ClinicalTrials.gov study NCT06927986. IPD Sharing: Not stated. Countries: 1. Publications: 0.
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
ClinicalTrials.gov study NCT06020066. IPD Sharing: NO. Countries: 1. Publications: 0.
Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial
ClinicalTrials.gov study NCT04553887. IPD Sharing: YES. Countries: 1. Publications: 0.
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
ClinicalTrials.gov study NCT05394233. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Me
ClinicalTrials.gov study NCT06667076. IPD Sharing: YES. Countries: 12. Publications: 0.
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
ClinicalTrials.gov study NCT03300115. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
ClinicalTrials.gov study NCT06730477. IPD Sharing: NO. Countries: 1. Publications: 0.
Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer
ClinicalTrials.gov study NCT06595498. IPD Sharing: NO. Countries: 1. Publications: 0.
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
ClinicalTrials.gov study NCT03732352. IPD Sharing: Not stated. Countries: 1. Publications: 0.
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
ClinicalTrials.gov study NCT07070440. IPD Sharing: NO. Countries: 1. Publications: 0.
A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
ClinicalTrials.gov study NCT01131429. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
ClinicalTrials.gov study NCT02332512. IPD Sharing: Not stated. Countries: 1. Publications: 0.
5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab
ClinicalTrials.gov study NCT07124884. IPD Sharing: NO. Countries: 4. Publications: 0.
Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC
ClinicalTrials.gov study NCT03374280. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT01312337. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation
ClinicalTrials.gov study NCT03810872. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.